{"documentId":"1Q4LifecycleMgmtRoadmap2026_uvw543XyZ12AbCdEfGhIjK","title":"Lifecycle Management Roadmap — 2026-2030","revisionId":"rev-1Q4Lifecycle","body":{"content":[{"sectionBreak":{"sectionStyle":{"columnSeparatorStyle":"NONE","contentDirection":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":59,"textRun":{"content":"Zenvara/Veltarix Lifecycle Management Roadmap — 2026-2030\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"TITLE","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":170,"textRun":{"content":"Prepared by LCM Strategy Lead. Distribution: Executive committee, Clinical Development, Regulatory Affairs, Global Value & Access, Commercial leadership. Annual review.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":19,"textRun":{"content":"Executive summary\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":481,"textRun":{"content":"The 2026-2030 Lifecycle Management Roadmap outlines the indication expansion, formulation development, and combination program strategy for the Zenvara/Veltarix franchise. The strategic objective is to maximize the addressable lifetime patient population and the post-IRA-MFP commercial position by 2032. Three indication expansions, one new formulation, and three combination programs are in active development. The combined LCM investment is estimated at $1.8B over the period.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":35,"textRun":{"content":"Indication expansion programs (3)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":420,"textRun":{"content":"Program 1 — 2L NSCLC re-treatment (ZENITH-2). Patient population: 1L IO progression, eligible for 2L re-treatment. Estimated annual addressable population (US): 8,400. Trial: Phase 3 randomized, ZENITH-2 vs investigator's choice. Currently enrolling, target 540 patients, anticipated readout Q3 2026. If positive, indication expansion sNDA filed Q1 2027, approval expected Q3 2027. Year-3 net revenue uplift: $80-120M.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":421,"textRun":{"content":"Program 2 — Adjuvant breast cancer (HER2-positive, post-surgery). Patient population: HER2-positive breast cancer post-surgical resection at high risk of recurrence. Estimated annual addressable population (US): 28,000. Trial: Phase 3 design under development; FDA Type B meeting scheduled Q3 2026. If favorable Type B outcome, Phase 3 starts H1 2027 with anticipated readout 2031. Year-7 net revenue uplift: $180-260M.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":509,"textRun":{"content":"Program 3 — Pediatric AML (acute myeloid leukemia). Patient population: pediatric AML, age 1-18. Estimated annual addressable population (US): 600. Regulatory pathway: pediatric investigation plan (PIP) under preparation; EMA scientific advice in Q2 2026; FDA PMR + pediatric exclusivity sought. Phase 2 enrolling, anticipated readout 2028. Year-5 net revenue uplift: minimal direct (small population) but unlocks 6-month pediatric exclusivity extension (worth approximately $250M in patent-life economics).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":25,"textRun":{"content":"Formulation development\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":456,"textRun":{"content":"Program 4 — Subcutaneous reformulation. Current formulation: 480mg IV infusion every 6 weeks (45 min infusion time). Subcutaneous formulation: 720mg SC injection every 4 weeks (5 min injection). Phase 1 PK bridging study in progress; bridging accepted by FDA if AUC ratio is 0.85-1.15 of IV at steady state. If bridging successful, formulation switch can be filed without a full new Phase 3, on a 12-month review timeline. Anticipated market entry: 2030.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":281,"textRun":{"content":"Strategic rationale for SC: enables outpatient and home-based administration, reduces infusion-center load, creates a parallel product not subject to the existing IRA MFP. The MFP applies to the specific NDC; SC formulation is a new NDC and resets the 7-year IRA selection clock.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":32,"textRun":{"content":"Investment: $42M over 4 years.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":26,"textRun":{"content":"Combination programs (3)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":353,"textRun":{"content":"Program 5 — Zenvara + chemotherapy combination (1L NSCLC PD-L1 1-49%). Trial: IMpact-2, Phase 3, currently enrolling. Designed to extend Zenvara into the PD-L1 1-49% subset where single-agent immunotherapy has insufficient benefit. Patient population (US): approximately 18,000 annually. Readout target Q4 2026. If positive, indication expansion 2027.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":261,"textRun":{"content":"Program 6 — Zenvara + ADC combination (HER3-targeted ADC). Phase 1b/2 in advanced NSCLC. Combination with a HER3 antibody-drug conjugate from our partner Daiichi Sankyo. Early data suggests synergy in HER3-expressing tumors. Phase 3 transition decision: 2027.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":175,"textRun":{"content":"Program 7 — Zenvara + LAG-3 combination. Phase 1b in advanced NSCLC post-IO. Combination with a LAG-3 antibody (in-license). Early data ambiguous; Phase 2 decision: H2 2026.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":22,"textRun":{"content":"Geographic expansion\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":162,"textRun":{"content":"EU launch (Germany, UK, France, Italy, Spain): Year 2 in Germany (current); UK Year 3 (post-NICE); France Year 4 (post-HAS); Italy + Spain Year 4 (post-EU JCA).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":65,"textRun":{"content":"Canada launch: Year 3 (post-CDA-AMC). pCPA pricing in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":102,"textRun":{"content":"Japan launch: Year 2 (H2 2026). Japan PMDA review concluded Q1 2026; reimbursement decision Q4 2026.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":92,"textRun":{"content":"China launch: Year 4. Strategic decision pending; potential partner-led commercialization.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":54,"textRun":{"content":"Latin America: Year 4-5. Mexico, Brazil prioritized.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":20,"textRun":{"content":"Investment summary\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":52,"textRun":{"content":"ZENITH-2 (2L) program: $210M completed by readout.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":65,"textRun":{"content":"Adjuvant breast Phase 3: $480M over 4 years (starting H1 2027).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":30,"textRun":{"content":"Pediatric AML program: $32M.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":48,"textRun":{"content":"Subcutaneous reformulation: $42M over 4 years.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":44,"textRun":{"content":"IMpact-2 combination: $180M (in progress).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":80,"textRun":{"content":"HER3 ADC combination: $120M (estimated, contingent on Phase 1b/2 progression).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":71,"textRun":{"content":"LAG-3 combination: $58M (Phase 1b/2 only; Phase 3 decision separate).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":75,"textRun":{"content":"Geographic expansion (regulatory + commercial setup): $620M over 5 years.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":59,"textRun":{"content":"Total LCM investment: approximately $1.8B over 2026-2030.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":18,"textRun":{"content":"Expected returns\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":169,"textRun":{"content":"Year-5 cumulative incremental net revenue from LCM programs: $1.2-1.6B (range reflects ZENITH-2 binary plus IMpact-2 binary plus adjuvant breast probability-weighted).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":56,"textRun":{"content":"Year-10 cumulative incremental net revenue: $4.8-7.2B.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":35,"textRun":{"content":"5-year ROI: approximately 60-80%.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":14,"textRun":{"content":"Risk profile\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":131,"textRun":{"content":"ZENITH-2 binary: highest near-term risk. Negative readout removes 2L pathway and reduces Year-3+ trajectory by $80-120M annually.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":158,"textRun":{"content":"FDA Type B outcome for adjuvant breast: medium risk. Negative outcome delays Phase 3 by 12-18 months and reduces Year-7 contribution by approximately $100M.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":135,"textRun":{"content":"PK bridging for SC formulation: medium risk. Failed bridging requires full new Phase 3 ($200M+ incremental investment, 5-year delay).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":127,"textRun":{"content":"IRA MFP severity (Scenario A): structural risk. Mitigated through SC formulation and indication expansion but not eliminated.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":16,"textRun":{"content":"Decision gates\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":73,"textRun":{"content":"Q3 2026: ZENITH-2 readout. Triggers either 2L pathway or repositioning.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":66,"textRun":{"content":"Q3 2026: FDA Type B for adjuvant breast. Triggers Phase 3 start.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":97,"textRun":{"content":"Q4 2026: IMpact-2 readout. Triggers either combination indication expansion or program closure.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":111,"textRun":{"content":"Q3 2027: SC reformulation PK bridging readout. Triggers either formulation switch filing or full new Phase 3.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":72,"textRun":{"content":"Q3 2028: Pediatric AML Phase 2 readout. Triggers PIP closure decision.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":89,"textRun":{"content":"Annual: post-Q4 board review of the LCM portfolio with go/no-go on continuing programs.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":18,"textRun":{"content":"Cross-references\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":139,"textRun":{"content":"2026 Commercial Plan (1P1…), IRA Negotiation Impact Analysis (1G6…), Evidence Dossier Index (1I8…), Competitor Monitoring Tracker (1N5…).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}}]},"documentStyle":{"pageNumberStart":1,"marginTop":{"magnitude":72,"unit":"PT"},"marginBottom":{"magnitude":72,"unit":"PT"},"marginLeft":{"magnitude":72,"unit":"PT"},"marginRight":{"magnitude":72,"unit":"PT"},"pageSize":{"height":{"magnitude":792,"unit":"PT"},"width":{"magnitude":612,"unit":"PT"}}},"namedStyles":{"styles":[{"namedStyleType":"NORMAL_TEXT","textStyle":{"fontSize":{"magnitude":11,"unit":"PT"}}},{"namedStyleType":"TITLE","textStyle":{"fontSize":{"magnitude":26,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_1","textStyle":{"fontSize":{"magnitude":20,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_2","textStyle":{"fontSize":{"magnitude":16,"unit":"PT"},"bold":true}}]},"lists":{},"inlineObjects":{},"headers":{},"footers":{},"footnotes":{},"suggestionsViewMode":"DEFAULT_FOR_CURRENT_ACCESS"}